Merck & Co Inc:Merck Announces Pause In Enrollment For Two Phase 3 Clinical Trials Of Investigational, Once-Monthly, Oral Islatravir For Pre-Exposure Prophylaxis (Prep) Of Hiv-1 Infection.
Merck & Co Inc - Enrolled Participants Will Continue To Receive Study Medicine.Merck & Co Inc - Informed By Recommendations Of Prep Edmc, Merck Is Implementing Additional Monitoring Measures For Study Participants.
Merck & Co Inc - Additional Monitoring Measures For Study Participants Include Increasing Frequency Of Total Lymphocyte And Cd4+ T-Cell Assessments.
Merck - At Isl Prep Edmc Recommendation, Pausing Impower 22, Impower 24 Enrollment While Co Conducts Further Analyses Of These, Other Ongoing Studies.Merck & Co Inc - Investigators Have Been Informed Of Actions Co Is Taking.